What Influences Physicians' Decisions About Patient Suitability for Biosimilar Infliximab?
Three Insulin Makers Face Class-Action Lawsuit on Price Fixing
FDA Filing of Sandoz's Humira Biosimilar Delayed
FDA Hiring Freeze Could Slow Down Biosimilar Approval Process
Novartis: The Company at the Forefront of Biosimilar Development
EMA Committee Recommends Approval of Amgen's Adalimumab Biosimilar
Novartis's Enbrel Biosimilar Marketing Delayed
The Supreme Court: Amgen v. Sandoz Briefing Schedule
Are Biosimilars Potential Market Disruptors?
EMA Launching Pilot to Support Biosimilars Development
FDA Releases Draft Guidance on Biosimilar Interchangeability
Biosimilars for Psoriasis: Spain's Dermatologists Weigh In
Instagram Pages
Here you can access stories featured on our instagram page. Want more biosimilar news? Sign up for our weekly newsletter, delivered to your inbox every Wednesday here.
FDA Extends NDA Review Period for New RA Treatment Expected to Compete with Humira
Biologics Mixing, Diluting, and Repackaging: FDA Draft Guidance
Boehringer Ingelheim Adalimumab Biosimilar Accepted for Review by FDA and EMA
Biogen's Tecfidera Settles Intellectual Patent Dispute
Pfizer Announces Positive Trial Results for Potential Humira Biosimilar
Bristol-Myers Squibb and GeneCentric Diagnostics Exploring Lung Cancer Biomarker Research
Breaking: US Supreme Court to Hear Biosimilars Lawsuits
Which road will the courts take?
What Lies Ahead for the Big Three RA Drugs?
Bio Relief: US FDA Rules On Biosimilars Naming
The suspense is over: the US Food and Drug Administration (FDA) has made their decision.
News and Views in Healthcare: This Weekend's Top 3 Reads
What's on our radar in the healthcare world.
US FDA Accepts Mylan Biologics License Application (BLA)
Decision slated for early September.
Should Biosimilars Be Interchangeable with Biologics?
Interchangeability is the real question.
News and Views in Healthcare: Today's Top 3 Reads
Today's top healthcare news with a focus on the biosimilars industry.
Biotech Movers and Shakers: Eye on Oncobiologics
We'll feature the latest biotechnolology "movers and shakers"--and how they are impacting the biosimilars industry.
What President Trump Means for Big Pharma
Patients may save money on prescriptions---and cut down pharma's profits.
Medicare Reimbursing for Inflectra, Pfizer's Infliximab Biosimilar
The New Wrinkle in the US Biosimilars Approval Process
GPhA takes issue with FDA timeline.